Cancer signaling networks in tumor progression and drug resistance: Crosstalk, adaptive reprogramming and therapeutic targeting (Review)
Oncology Reports · 2026
DOI: 10.3892/or.2026.9131 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Oncology Reports, 2026. Verfasst von Hongyan Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Department of Integrated Traditional Chinese and Western Medicine, Shenyang Tenth People's Hospital, Shenyang, Liaoning 110044, P.R. China. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Neoplasms, Signal Transduction. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 163 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Oncology Department of Integrated Traditional Chinese and Western Medicine, Shenyang Tenth People's Hospital, Shenyang, Liaoning 110044, P.R. China.
- Department of Thoracic Surgery, Shenyang Tenth People's Hospital, Shenyang, Liaoning 110044, P.R. China.
Zitieren
APA
Li, H., Song, S., Wang, L., & Liu, Q. (2026). Cancer signaling networks in tumor progression and drug resistance: Crosstalk, adaptive reprogramming and therapeutic targeting (Review). Oncology Reports. https://doi.org/10.3892/or.2026.9131
Vancouver
Li H, Song S, Wang L, Liu Q. Cancer signaling networks in tumor progression and drug resistance: Crosstalk, adaptive reprogramming and therapeutic targeting (Review). Oncology Reports. 2026. doi:10.3892/or.2026.9131
BibTeX
@article{Li2026,
author = {Li, Hongyan and Song, Shiyuan and Wang, Linlin and Liu, Qiang},
title = {Cancer signaling networks in tumor progression and drug resistance: Crosstalk, adaptive reprogramming and therapeutic targeting (Review)},
journal = {Oncology Reports},
year = {2026},
doi = {10.3892/or.2026.9131}
}
EUVIMED